Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
NCT02555189 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · PHASE1/PHASE2 · terminated · last registry update 2026-04-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib to standard of care enzalutamide did not demonstrate benefit, an all active subjects were removed from the study.” | – | Registry record, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-09Results posted on the registry: Alliance Foundation Trials, LLC., Apalutamide + LHRH Analogue (NCT03009981)
- 2026-10-27Phase 3 first posted: Amneal Pharmaceuticals, LLC, Testosterone Cypionate 75 mg + Testosterone cypionate 50 mg (NCT07898072)
- 2026-10-27Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Danazol (NCT03312400)
- 2026-10-27Also stopped (terminated): National Heart, Lung, and Blood Institute (NHLBI), Danazol (NCT03312400)
- 2026-10-21Phase 3 first posted: Khyber Medical University Peshawar, Thalidomide + Danazol (NCT07884773)
- 2026-10-02Also stopped (withdrawn): Tulane University, XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector (NCT04601233)
- 2026-10-01Phase 3 first posted: ECOG-ACRIN Cancer Research Group, Abiraterone Acetate + Cabazitaxel (NCT07852195)
- 2026-09-29Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Testosterone Undecanoate + Enzalutamide (NCT05081193)
- 2026-09-17Also stopped (terminated): Jefferson Drapkin, Vaginal Cream with Applicator (NCT04807894)
- 2026-09-02Results posted on the registry: University of Colorado, Denver, Gonadotropin Releasing Hormone Agonists (GNRH) + Androgen receptor (AR) inhibitor (NCT05700903)
- 2026-09-02Also stopped (terminated): University of Colorado, Denver, Gonadotropin Releasing Hormone Agonists (GNRH) + Androgen receptor (AR) inhibitor (NCT05700903)
- 2026-08-03Phase 3 first posted: VA Office of Research and Development, testosterone cypionate + finasteride (NCT07742553)
- 2026-07-16Results posted on the registry: Dana-Farber Cancer Institute, Testosterone Cypionate 100 MG/ML + Placebo (NCT03716739)
- 2026-07-02Results posted on the registry: Washington University School of Medicine, Androgen deprivation therapy (NCT05628363)
- 2026-05-07Results posted on the registry: Brigham and Women's Hospital, Testosterone Undecanoate (NCT03576001)
- 2026-05-07Also stopped (terminated): University of Southern California, Oxandrolone + Placebo (NCT03091075)
- 2026-03-27Also stopped (suspended): George F. Hatch, Oxandrolone + Placebo (NCT05893069)
- 2025-12-23Results posted on the registry: VA Office of Research and Development, Testosterone gel 1.62% + Placebo (NCT03887936)
- 2025-09-23Also stopped (withdrawn): OHSU Knight Cancer Institute, Gonadotropin Releasing Hormone Agonists and Antagonists + Bicalutamide (NCT06528210)
- 2025-08-05Also stopped (terminated): The University of Queensland, Danazol + Placebo (NCT04638517)
- 2025-07-31Phase 3 first posted: Jaeb Center for Health Research, Atropine + Placebo Eyedrops (NCT07095894)
- 2025-07-22Also stopped (terminated): University of California, San Diego, Testosterone Cypionate 50 MG/ML Injectable Solution (NCT06450405)
- 2025-07-22Also stopped (withdrawn): University of Nebraska, Bicalutamide (NCT06501911)
- 2025-07-14Results posted on the registry: University of California, San Diego, Testosterone Cypionate 50 MG/ML Injectable Solution (NCT06450405)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision